Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2014 | A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. | CLINICAL CANCER RESEARCH |